Lauwers M H, Vanlersberghe C, Camu F
Department of Anesthesiology, Flemish Free University of Brussels School of Medicine, Belgium.
Reg Anesth Pain Med. 1998 Jan-Feb;23(1):64-70. doi: 10.1016/s1098-7339(98)90112-2.
Patients treated with regional anesthesia often require concomitant medication for comfort and sedation. Propofol is widely used for this purpose. Remifentanil, a new ultra-short-acting opioid, exhibits at low doses distinct sedative properties that may be useful for supplementation of regional anesthesia. This study compared the effectiveness of remifentanil and propofol infusions for providing sedation during regional block placement and surgery.
In an open, prospective trial, 28 patients were randomly allocated to receive continuous infusions of remifentanil (6 microg/kg/h) or propofol (3 mg/kg/h) for sedation during spinal or axillary regional anesthesia. Infusion rates were titrated to maintain a sedation level > or = 2 as assessed with the Observer's Assessment of Alertness Scale. Vital signs were measured continuously, during and for 2 hours after ending study drug infusion.
Similar scores for comfort and sedation were obtained in both groups during placement of the regional block and during surgery. Degree of sedation correlated with drug infusion rate of remifentanil (P < .002) but not for propofol. Respiratory rate decreased in the remifentanil group in absence of surgery (P < .05). Mean arterial pressure and heart rate were 20% lower in the propofol group (P < .05). Return to alertness occurred after 10 +/- 6 minutes in the remifentanil group and after 16 +/- 15 minutes in the propofol group. Similar incidences of hypotension, bradycardia, and nausea and vomiting were found in both groups, but intraoperative respiratory depression and nausea were more prominent in the remifentanil group.
When titrated to the same sedation level, remifentanil provided a smoother hemodynamic profile than propofol during regional anesthesia. The frequent occurrence of remifentanil-induced respiratory depression requires cautious administration of this agent. The incidence of adverse reactions seen with both agents during and after their administration makes the management of such sedative infusion techniques difficult.
接受区域麻醉的患者常需辅助用药以获得舒适感和镇静效果。丙泊酚广泛用于此目的。瑞芬太尼是一种新型超短效阿片类药物,小剂量时即具有明显的镇静特性,可能有助于区域麻醉的辅助用药。本研究比较了瑞芬太尼和丙泊酚输注在区域阻滞置管和手术期间提供镇静的效果。
在一项开放、前瞻性试验中,28例患者被随机分配在脊髓或腋路区域麻醉期间接受瑞芬太尼(6微克/千克/小时)或丙泊酚(3毫克/千克/小时)持续输注以进行镇静。输注速率根据观察者警觉性评估量表评估维持镇静水平≥2进行滴定。在研究药物输注期间及结束后2小时连续测量生命体征。
在区域阻滞置管和手术期间,两组在舒适度和镇静方面获得了相似的评分。镇静程度与瑞芬太尼的药物输注速率相关(P<.002),但与丙泊酚无关。在无手术情况下,瑞芬太尼组呼吸频率降低(P<.05)。丙泊酚组平均动脉压和心率低20%(P<.05)。瑞芬太尼组在10±6分钟后恢复清醒,丙泊酚组在16±15分钟后恢复清醒。两组低血压、心动过缓以及恶心呕吐的发生率相似,但术中呼吸抑制和恶心在瑞芬太尼组更突出。
在区域麻醉期间,当滴定至相同镇静水平时,瑞芬太尼比丙泊酚提供更平稳的血流动力学状态。瑞芬太尼引起的呼吸抑制频繁发生,需要谨慎使用该药物。两种药物在给药期间及给药后出现的不良反应发生率使得此类镇静输注技术的管理变得困难。